Alpine Immune Sciences (ALPN) signed a definitive agreement with Vertex Pharmaceuticals (VRTX) . Per the terms, the pharma giant will acquire all outstanding shares of Alpine for $65 per share in cash, aggregating to$4.9 billion. A clinical-stage pharmaceutical company, Alpine is engaged in the development of multi-functional therapies targeting both autoimmune and inflammatory diseases. The acquisition will also include Alpine’s lead asset, povetacicept (formerly ALPN-303), designed to target two proteins ...